[Unspecific vaccination].

H Stickl

Home/Archive/PubMed

PubMed · 6168550

[Unspecific vaccination].

H Stickl

View original source ↗Export metadata ↓

Abstract

All vaccines have--besides their specific effect on the immune response--more or less pronounced side effects on the organism and particularly on the immune system. The latter effects deserve special interest, whenever they increase the host defence against infectious diseases. Desirable paraspecific effects of vaccines are the induction of interferon, the enhancement of phagocytic function and the activation of lysosomal enzymes. Some vaccines exert different effects: attenuated live measles vaccine induces interferon, pertussis vaccine activates lysosomal enzymes of macrophages. Some clinical observations illustrate how paraspecific effects of vaccines can be utilized for therapeutic purposes.

Explore related subjects

Glucan 1,4-alpha-Glucosidase Humans Interferons Macrophages Measles Vaccine Pertussis Vaccine T-Lymphocytes Vaccination English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H Stickl. 1980-12-11. [Unspecific vaccination].. https://pubmed.ncbi.nlm.nih.gov/6168550/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.

We describe a boy with an early lethal hypertrophic vacuolar cardiomyopathy of neonatal onset. Abnormal intra- and extralysosomal glycogen storage disease was demonstrated in heart and skeletal muscles. Glycogen content was twice the normal in muscles and over 3-fold the normal in the heart. In this organ, over 50% of the intracellular space was occupied by glycogen and possibly oligosaccharides, as demonstrated by the quantitative morphometric analysis of electron micrographs. The activity of acid alpha-glucosidase was increased in the heart, skeletal muscles, and liver, but was normal in leukocytes. A review of the 11 previously published pedigrees of lysosomal glycogen storage disease with normal in vitro alpha-glucosidase activity allows the delineation of three clinical entities: juvenile and neonatal pseudo-Pompe diseases and partial Pompe disease. Partial Pompe disease, due to the tissue-specific absence of acid alpha-glucosidase, was observed in a single patient. The most common form is the late-onset pseudo-Pompe disease, which is characterized by severe cardiomyopathy and mild myopathy appearing in the second or third decade, prominent arrhythmia with Wolf-Parkinson-White syndrome, and sometimes mental retardation. Patients reported as suffering from Antopol disease probably belong to this group. Dominant inheritance (autosomal or X linked) is likely in most families. The present report appears to be the first one to describe a rapidly fatal neonatal form of lysosomal glycogenosis without acid maltase deficiency. The mode of inheritance of this form is not known. Differential diagosis includes Pompe disease (similar histology) and cardiac phosphorylase b kinase deficiency (similar clinical course). The delineation of neonatal pseudo-Pompe disease makes enzymatic confirmation mandatory in each case suspected of Pompe disease.

Glucan 1,4-alpha-Glucosidase↗

PubMed1996

[Degradation of Maillard reaction products by amylolytic enzymes. 3. Inhibition of glucoamylase, alpha-amylase and alpha-glucosidase by heat treated alpha-glucans and melanoidins].

Amylolytic enzymes are only slightly inhibited by thermal treated alpha-glucans (10-15%). The addition of glycine to the thermolysis mixture produces no increase of the inhibition. The inhibition of the enzyme activity is probably caused by short-chain alpha-glucans that the secondary binding places of the active centre coat and therefore the hydrolysis is reduced. Glucoamylase and alpha-amylase are not inhibited by non-dialysed melanoidines from the reaction of D-glucose and glycine, but there is a strong inhibition of alpha-glucosidase by these melanoidines (up to 45%). Strongly coloured, low molecular compounds that are formed during the Maillard-reaction and are soluble in ethyl acetate cause no inhibition of Glucoamylase and alpha-amylase.

Glucan 1,4-alpha-Glucosidase↗

PubMed1995

Glycogenosis type II (acid maltase deficiency).

Glycogen storage disease type II (GSD II/glycogenosis type II/Pompe's disease/acid maltase deficiency) is caused by the deficiency of lysosomal alpha-glucosidase resulting in lysosomal accumulation of glycogen. The disease is inherited as an autosomal recessive trait and is clinically heterogeneous. Early and late onset phenotypes are distinguished. Insight in the molecular nature of the lysosomal alpha-glucosidase deficiency and the underlying genetic defect has increased significantly during the past decade. This minireview on GSD II was written at the occasion of The International Symposium on Glycolytic and Mitochondrial Defects in Muscle and Nerve, held in Osaka, Japan, July 1994. It is an update of current literature, but also includes original data from the collaborating authors on mutations occurring in the lysosomal alpha-glucosidase gene and on prenatal diagnosis by chorionic villus sampling. The genotype-phenotype correlation and the prospects for therapy are addressed.

Glucan 1,4-alpha-Glucosidase↗